Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities researchers at Jefferies Group cut their FY2017 earnings estimates for shares of Vanda Pharmaceuticals in a research note issued to investors on Tuesday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will post earnings per share of ($0.52) for the year, down from their prior estimate of ($0.51). Jefferies Group currently has a “Buy” rating and a $21.00 target price on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ FY2018 earnings at ($0.33) EPS.
A number of other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 18th. TheStreet upgraded shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Friday, May 12th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $23.00 target price on shares of Vanda Pharmaceuticals in a research note on Tuesday, June 27th. HC Wainwright began coverage on shares of Vanda Pharmaceuticals in a research note on Friday, May 26th. They issued a “buy” rating and a $18.00 target price for the company. Finally, BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $21.25.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/fy2017-eps-estimates-for-vanda-pharmaceuticals-inc-vnda-cut-by-analyst/1565965.html.
Vanda Pharmaceuticals (VNDA) opened at 17.20 on Thursday. The stock’s market capitalization is $771.56 million. Vanda Pharmaceuticals has a one year low of $12.70 and a one year high of $18.00. The firm has a 50-day moving average of $16.12 and a 200 day moving average of $14.96.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.18. The business had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.01 earnings per share.
A number of hedge funds have recently added to or reduced their stakes in VNDA. Legal & General Group Plc boosted its stake in Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 3,022 shares during the period. Kopp Investment Advisors LLC bought a new stake in Vanda Pharmaceuticals during the second quarter worth approximately $196,000. Virginia Retirement Systems ET AL bought a new stake in Vanda Pharmaceuticals during the first quarter worth approximately $193,000. Capital Fund Management S.A. bought a new stake in Vanda Pharmaceuticals during the first quarter worth approximately $195,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Vanda Pharmaceuticals during the first quarter worth approximately $196,000. Institutional investors own 86.49% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.